MYH2 siRNA (h): sc-106273



The Power to Question

BACKGROUND

Myosin is a highly conserved, ubiquitously expressed protein that interacts with Actin to generate the force for cellular movements. Conventional Myosins are hexameric proteins consisting of two heavy chain subunits, a pair of non-phosphorylatable light chain subunits and a pair of phosphorylatable light chain subunits. Three general classes of Myosin have been cloned: smooth muscle Myosins, striated muscle Myosins and non-muscle Myosins. Contractile activity in smooth muscle is regulated by the calcium/calmodulin-dependent phosphorylation of Myosin light chain (MLC) by Myosin light chain kinase. Myosin heavy chains, which are encoded by the MYH gene family, contain Actin-activated ATPase activity which generates the motor function of Myosin. Myosin heavy chains were initially isolated from a human fetal skeletal muscle and are the major determinant in the speed of contraction of skeletal muscle. Various isoforms of Myosin heavy chains are differentially expressed depending on the functional activity of the muscle.

REFERENCES

- Saez, C.G., et al. 1990. Human nonmuscle Myosin heavy chain mRNA: generation of diversity through alternative polyadenylylation. Proc. Natl. Acad. Sci. USA 87: 1164-1168.
- 2. Hughes, S.M., et al. 1992. Muscle fiber pattern is independent of cell lineage in postnatal rodent development. Cell 68: 659-671.
- Lalwani, A.K., et al. 2000. Human nonsyndromic hereditary deafness DFNA17 is due to a mutation in nonmuscle myosin MYH9. Am. J. Hum. Genet. 67: 1121-1128.
- Seri, M., et al. 2000. Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/Fechtner Syndrome Consortium. Nat. Genet. 26: 103-105.
- Heath, K.E., et al. 2001. Nonmuscle Myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes. Am. J. Hum. Genet. 69: 1033-1045.
- Deutsch, S., et al. 2003. Asp1424Asn MYH9 mutation results in an unstable protein responsible for the phenotypes in May-Hegglin anomaly/Fechtner syndrome. Blood 102: 529-534.

CHROMOSOMAL LOCATION

Genetic locus: MYH2 (human) mapping to 17p13.1.

PRODUCT

MYH2 siRNA (h) is a pool of 2 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μM solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see MYH2 shRNA Plasmid (h): sc-106273-SH and MYH2 shRNA (h) Lentiviral Particles: sc-106273-V as alternate gene silencing products.

For independent verification of MYH2 (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-106273A and sc-106273B.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNAse-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNAse-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

MYH2 siRNA (h) is recommended for the inhibition of MYH2 expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 µM in 66 µl. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

GENE EXPRESSION MONITORING

MYH2 (A4.74): sc-53095 is recommended as a control antibody for monitoring of MYH2 gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-lgG κ BP-HRP: sc-516102 or m-lgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz MarkerTM Molecular Weight Standards: sc-2035, UltraCruz[®] Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-lgG κ BP-FITC: sc-516140 or m-lgG κ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz[®] Mounting Medium: sc-24941 or UltraCruz[®] Hard-set Mounting Medium: sc-359850.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor MYH2 gene expression knockdown using RT-PCR Primer: MYH2 (h)-PR: sc-106273-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3800 fax 831.457.3801 **Europe** +00800 4573 8000 49 6221 4503 0 **www.scbt.com**